Boceprevir
Hepatitis C
Hospices Civils de LyonSmall moleculePhase 4 / ApprovedDormant
BBB
75/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 61/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Hepatitis C cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Daclatasvir MTI University | Phase 4 | A |
Sofosbuvir Peking University People's Hospital | Phase 4 | A |
Ribavirin Peking University People's Hospital | Phase 4 | A |
Simeprevir University of Colorado, Denver | Phase 4 | A |
Pegylated Interferon Alpha2A Tanta University | Phase 4 | A |
View all 50 →
Same molecule, other indications
Boceprevir is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →